CrossBridge is on a mission to help achieve the best outcomes at the lowest possible cost for all chronic inflammatory disease.
CrossBridge resulted from the vision of Bill Conlan, who has deep experience in the application of the latest technologies to meet challenges in healthcare. Bill’s resolve to attack chronic inflammatory disease comes from his own experience with ankylosing spondylitis.
Chief Executive Officer
Bill has a 27-year history of employing the latest technologies to meet challenges in health care. Most recently, Bill co-founded HealthQx, a value-based payment analytics company relied on by payers with 45 million total members. HealthQx was acquired by McKesson in 2016, and renamed Change Healthcare. Read More. Previously, Bill founded Healthcare Data Management (HDM), a pioneer in modeling employee health benefit plans and using data-driven metrics to monitor health plan spend. HDM was acquired by Thomson Reuters in 2010 and is now part of IBM Watson. CrossBridge is a mission for Bill, who has ankylosing spondylitis. He also has family members with rheumatoid arthritis and multiple sclerosis.
Chief Operating Officer
Susan co-founded Eviti, Inc., which became the leading oncology decision-support platform and healthcare payer reimbursement SaaS-based platform in the U. S. The platform connects providers and payers at the critical moments of clinical need. Treatment plan data is shared in real time, connecting all pertinent stakeholders for appropriate reimbursement and optimal patient management. The Eviti customer base includes national and regional payers with 30 million members across all lines of medical health insurance – fully insured, self-insured, Medicare, Medicaid, Federal government plans and TPAs. The platform was adopted by payers and associated provider networks in all 50 states.
Bruce Freundlich, MD
Chief Medical Officer
Dr. Bruce Freundlich is skilled in clinical research and medical affairs, with expertise in Rheumatology, Dermatology, Endocrinology and Neuro-psychiatry. Dr. Freundlich was Senior Vice president, Medical at Antares Pharmaceuticals and Vice President Inflammation and Vice President, Global Medical Affairs at Pfizer Pharmaceuticals over a nine-year period. Among other accomplishments, he was responsible for post-marketing Enbrel trials. Dr. Freundlich also served as Chief of Clinical Rheumatology at the University of Pennsylvania for more than six years.